The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,193,692 in first-year total cost, median $1,096,846.
Most frequent study sections
- Special Emphasis Panel[ZAA1 DD (11)]2
Most frequent institutions
- AMYGDALA NEUROSCIENCES, INC.1
- COLORADO RESEARCH PARTNERS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder1U01AA027997-01 | JOHNSON, RICHARD JOSEPH | COLORADO RESEARCH PARTNERS, LLC, CO | $1,293,692 | ZAA1 |
| 2019 | 26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use Disorder Phase 3 Studies1U01AA028003-01 | DIAMOND, IVAN | AMYGDALA NEUROSCIENCES, INC., CA | $900,000 | ZAA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.